Market Overview

UPDATE: Piper Jaffray Reiterates Overweight Rating, Raises PT on Alnylam Pharmaceuticals

Related ALNY
The Biotech Stock With The Biggest Head Of Steam
Events Scheduled for Week of Jun 23rd to Jun 27th, 2014

In a report published Monday, Piper Jaffray reiterated its Overweight rating on Alnylam Pharmaceuticals (NASDAQ: ALNY), and raised its price target from $25.00 to $35.00.

Piper Jaffray noted, “Alnylam is the leading RNAi therapeutic play with clinical progress and partnerships to drive value in 2013. Alnylam recently raised net proceeds of $174 million, and we estimate now holds proforma cash of ~$405 million. We look for Phase II ALN-TTR02 data in FAP this summer to prepare the company for a pivotal trial by year-end. Alnylam just filed a CTA to begin a Phase I trial of the subcutaneous formulation ALN-TTRsc, and aims to begin a Phase II exploratory trial in FAC this year. Alnylam will file an IND for ALN-AT3 in hemophilia and announced a new '5x15' program ALN-AS1 to treat acute intermittent porphyria. We reiterate our Overweight rating and are increasing our price target to $35 from $25 by adding value for ALN-TTRsc.”

Alnylam Pharmaceuticals closed on Friday at $24.77.

Posted-In: Piper JaffrayAnalyst Color Price Target Analyst Ratings

 

Related Articles (ALNY)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters